ReviewFrontiers in medicine2020
Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification.
Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review.Medicina (Kaunas, Lithuania) · 2023Pooled it
- An Engineered Glove for the Objective Assessment of Hand Dexterity in Patients With Systemic Sclerosis.ACR open rheumatology · 2026Article
- Post-Acute Sequelae Patients with Severe COVID-19 History Show a Prolonged Inflammatory, Vascular Injury Pattern.European journal of immunology · 2026Article
- Article
- Bibliometric insights into systemic sclerosis with renal involvement: trends, contributions, and future directions.Renal failure · 2025Article
- Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis.The Journal of experimental medicine · 2025Article
- Paraneoplastic systemic sclerosis: A distinct entity or a mere association - A case report.Journal of family medicine and primary care · 2025Article
- HLA Association among Thai Patients with Diffuse and Limited Cutaneous Systemic Sclerosis.Biomedicines · 2024Article
- Peripheral and ocular microvascular alterations in systemic sclerosis: observations from capillaroscopic assessments, perfusion peripheral analysis, and optical coherence tomography angiography.Rheumatology international · 2024Article
- Polyneuropathy in systemic sclerosis: exploring the causes and biomarkers.Frontiers in medicine · 2024Article
- Clinical Risk Factors for Dysphagia and Esophageal Dysmotility in Systemic Sclerosis.Journal of clinical medicine · 2023Article
- Specific Autoantibodies and Microvascular Damage Progression Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: Are There Peculiar Associations? An Update.Antibodies (Basel, Switzerland) · 2023Review
- Extension-elicited blanching of the dorsal phalanges in systemic sclerosis: A case series.JAAD case reports · 2022Article
- The promise of precision medicine in rheumatology.Nature medicine · 2022Review
- Animal Models of Systemic Sclerosis: Using Nailfold Capillaroscopy as a Potential Tool to Evaluate Microcirculation and Microangiopathy: A Narrative Review.Life (Basel, Switzerland) · 2022Review
- Capillaroscopy and Immunological Profile in Systemic Sclerosis.Life (Basel, Switzerland) · 2022Article
- Increased L-Selectin on Monocytes Is Linked to the Autoantibody Profile in Systemic Sclerosis.International journal of molecular sciences · 2022Article
- Autoreactive B cells recruited to lungs by silica exposure contribute to local autoantibody production in autoimmune-prone BXSB and B cell receptor transgenic mice.Frontiers in immunology · 2022Article
- Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?Frontiers in immunology · 2022Review
- Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is an autoimmune disease characterized by abnormalities in microcirculation, extracellular matrix accumulation, and immune activation. Autoantibodies are markers of immune abnormalities and provide diagnostic and predictive value in SSc. Anti-topoisomerase antibodies (ATAs), anticentromere antibodies (ACAs), and anti-RNA polymerase antibodies (ARAs) are the three classical specific antibodies with the highest availability and stability. In this review, we provide an overview of the recent progress in SSc research with respect to ATAs, ACAs, and ARAs, focusing on their application in distinguishing clinical phenotypes, such as malignancy and organ involvement, identifying genetic background in human leukocyte antigen (HLA) or non-HLA alleles, and their potential roles in disease pathogenesis based on the effects of antigen-antibody binding. We finally summarized the novel analysis using ATAs, ACAs, and ARAs on more detailed disease clusters. Considering these advantages, this review emphasizes that classical SSc-specific autoantibodies are still practical and have the potential for patient and risk stratification with applications in precise medicine for SSc.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.